Overview of Sativex for MS spasticity: three pivotal clinical trials
Across three pivotal trials involving over 1,000 patients, Sativex consistently reduced MS spasticity scores compared to placebo, with mild and transient side effects.
Quick Facts
What This Study Found
This review summarized data from three pivotal randomized controlled trials of Sativex for MS-related spasticity. The first trial (189 patients, 6 weeks) showed a significant spasticity score reduction with Sativex versus placebo (-1.18 vs -0.63, p=0.048). The second trial (337 patients, 15 weeks) confirmed the finding (-1.3 vs -0.8, p=0.035).
The third trial used an innovative design: 572 patients first tried Sativex openly, and the 47% who responded (20% or greater improvement) were then randomized to continue Sativex or switch to placebo. Responders who continued Sativex maintained their improvement, while those switched to placebo worsened (p=0.0002).
No tolerance, withdrawal syndrome, or evidence of misuse or abuse was reported across trials. Side effects were mild-to-moderate and transient, primarily dizziness, fatigue, and somnolence.
Key Numbers
Trial 1: 189 patients, 6 weeks, p=0.048. Trial 2: 337 patients, 15 weeks, p=0.035. Trial 3: 572 patients, 47% initial responders, p=0.0002 for sustained efficacy. No tolerance or withdrawal reported.
How They Did This
Review of three pivotal randomized, placebo-controlled clinical trials of Sativex oromucosal spray in MS patients with resistant spasticity. Combined enrollment exceeded 1,000 patients. Primary endpoint was the 0-10 NRS spasticity score.
Why This Research Matters
This represented the strongest clinical trial evidence at the time for any cannabis-based medicine. The enriched enrollment design of the third trial was particularly important because it demonstrated that identifying responders first could improve treatment efficiency.
The Bigger Picture
These trials formed the regulatory basis for Sativex approval in multiple countries. The enriched enrollment design became a model for subsequent cannabis medicine trials, addressing the challenge of variable individual responses.
What This Study Doesn't Tell Us
Review by a single author. The NRS spasticity scale is subjective. The enriched enrollment design in trial 3, while practical, selects for patients who respond and may overestimate effect size for the general MS population.
Questions This Raises
- ?What predicts which MS patients will be Sativex responders?
- ?Does long-term use maintain efficacy beyond the trial periods?
- ?Could the enriched design approach improve other cannabis medicine trials?
Trust & Context
- Key Stat:
- 47% of patients were initial responders in the largest trial
- Evidence Grade:
- Review of three pivotal RCTs with combined enrollment exceeding 1,000 patients. Represents strong clinical evidence for this indication.
- Study Age:
- Published in 2011. Sativex has since been approved in over 25 countries for MS spasticity.
- Original Title:
- Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
- Published In:
- Expert review of neurotherapeutics, 11(4 Suppl), 15-9 (2011)
- Authors:
- Vermersch, Patrick
- Database ID:
- RTHC-00531
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How effective is Sativex for MS spasticity?
About 47% of patients in the largest trial showed meaningful improvement (20% or better) in spasticity scores. For those who respond, the benefits were sustained over months of treatment. Not everyone responds, which is why a trial period is recommended.
Does Sativex cause a high?
No significant intoxication was reported in clinical trials. The most common side effects were dizziness, fatigue, and somnolence, which were generally mild to moderate and could be reduced by gradually increasing the dose.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00531APA
Vermersch, Patrick. (2011). Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.. Expert review of neurotherapeutics, 11(4 Suppl), 15-9.
MLA
Vermersch, Patrick. "Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.." Expert review of neurotherapeutics, 2011.
RethinkTHC
RethinkTHC Research Database. "Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocann..." RTHC-00531. Retrieved from https://rethinkthc.com/research/vermersch-2011-sativex-tetrahydrocannabinol-cannabidiol-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.